Harwood Feffer Amends Class Action Complaint Against Genzyme Corporation (GENZ)

Harwood Feffer LLP today announced that on January 18, 2011 the firm amended its class action complaint against Genzyme Corporation GENZ and its Board of Directors to include claims of violations under Section 14 and Section 20 of the Securities Exchange Act of 1934. The complaint charges that the defendants breached their fiduciary duties to the Company's shareholders and violated the Securities Exchange Act of 1934. More specifically, the complaint alleges that defendants failed to disclose certain material facts in connection with the proposal to acquire the Company by Sanofi-Aventis, publicly announced on August 29, 2010, and that the 14D-9 defendants filed with the SEC on October 7, 2010 and disseminated to Genzyme shareholders thereafter, wherein the Board recommended shareholders not tender their shares, contained materially misleading information. The complaint also includes claims for breach of fiduciary duty. It is brought on behalf of a class of all Genzyme shareholders except for the named defendants and persons or entities related to or affiliated with the defendants.